BioCryst Pharmaceuticals, Inc. Stock price
Equities
BCRX
US09058V1035
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
5.22 USD | +1.36% | -5.85% | -14.02% |
Financials (USD)
Sales 2024 * | 397M | Sales 2025 * | 486M | Capitalization | 1.06B |
---|---|---|---|---|---|
Net income 2024 * | -116M | Net income 2025 * | -50M | EV / Sales 2024 * | 3.26 x |
Net Debt 2024 * | 234M | Net Debt 2025 * | 259M | EV / Sales 2025 * | 2.72 x |
P/E ratio 2024 * |
-8.95
x | P/E ratio 2025 * |
-18.3
x | Employees | 536 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.92% |
Latest transcript on BioCryst Pharmaceuticals, Inc.
1 day | +2.79% | ||
1 week | -5.85% | ||
Current month | -8.53% | ||
1 month | -12.27% | ||
3 months | -16.80% | ||
6 months | -31.52% | ||
Current year | -14.02% |
Managers | Title | Age | Since |
---|---|---|---|
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Anthony Doyle
DFI | Director of Finance/CFO | 44 | 20-04-01 |
Michael Jones
DFI | Director of Finance/CFO | 54 | 10-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Alan Levin
BRD | Director/Board Member | 62 | 20-02-26 |
Jon Stonehouse
CEO | Chief Executive Officer | 63 | 06-12-31 |
Director/Board Member | 60 | 21-07-25 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.23% | 0 M€ | 0.00% | - | |
0.20% | 0 M€ | 0.00% | - | |
0.18% | 907 M€ | +9.14% | - | |
0.13% | 464 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-03-27 | 5.15 | +2.79% | 2 990 374 |
24-03-26 | 5.01 | +2.04% | 3,159,988 |
24-03-25 | 4.91 | -2.00% | 2,828,319 |
24-03-22 | 5.01 | -8.74% | 3,296,041 |
24-03-21 | 5.49 | +0.37% | 2,726,058 |
Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.02% | 1.06B | |
+2.56% | 108B | |
+10.02% | 104B | |
+7.83% | 23.66B | |
-11.91% | 22.1B | |
-3.29% | 19.71B | |
-35.98% | 18.2B | |
-14.02% | 16.19B | |
+4.61% | 13.72B | |
+35.05% | 12.22B |